RESUMEN
In-vitro activity of 14 commercial pancreatin preparations, commonly used in the Federal Republic of Germany, were tested. All had been declared by their manufacturers to contain more than 6000 FIP (Fédération International Pharmaceutique) units of lipase and to be acid resistant. The declared lipase and amylase amounts were found to be present in 11 of the 14 preparations. Three of the 14 preparations, said to be acid resistant were found not to be so in buffer with falling pH values between 4.0 and 2.5, so that there occurred an, at times marked, loss of enzyme activity. Most noticeable was the poor solubility of most preparations at pH 6.6. Only three of the 14 liberated their total enzyme content within 60 minutes, as they should for theoretical reasons, based on the relatively short duodeno-cecal transit time.
Asunto(s)
Extractos Pancreáticos/normas , Amilasas/análisis , Amilasas/normas , Bromelaínas/análisis , Bromelaínas/normas , Ácido Deshidrocólico/análisis , Ácido Deshidrocólico/normas , Dimetilpolisiloxanos/análisis , Dimetilpolisiloxanos/normas , Combinación de Medicamentos/análisis , Combinación de Medicamentos/normas , Concentración de Iones de Hidrógeno , Lipasa/análisis , Lipasa/normas , Extractos Pancreáticos/análisis , Pancreatina/análisis , Pancreatina/normas , Solubilidad , Tripsina/análisis , Tripsina/normasRESUMEN
The activities of amylase, lipase, phospholipase and trypsin of twelve commercial pancreatic enzyme preparations were measured under identical conditions. Human small intestinal juice was chosen as incubation medium. A wide variation of enzymatic activities was found in preparations in tablet form contrary to preparations in granulated form. A prerequisite for a successful therapy is enzymically potent pancreatic extracts with high enzyme content per table, capsule or recommended dose of granulated preparation. Therefore, some preparations seem to be preferable to others for clinical purposes.